Relay Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Relay Therapeutics is Sanjiv Patel, benoemd in Mar2017, heeft een ambtstermijn van 7.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 19.77M, bestaande uit 3.4% salaris en 96.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.82% van de aandelen van het bedrijf, ter waarde $ 6.49M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.6 jaar en 5.3 jaar.
Belangrijke informatie
Sanjiv Patel
Algemeen directeur
US$19.8m
Totale compensatie
| Percentage CEO-salaris | 3.4% |
| Dienstverband CEO | 7.7yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Sep 11Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation
Aug 03
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$345m |
| Jun 30 2024 | n/a | n/a | -US$323m |
| Mar 31 2024 | n/a | n/a | -US$329m |
| Dec 31 2023 | US$20m | US$674k | -US$342m |
| Sep 30 2023 | n/a | n/a | -US$326m |
| Jun 30 2023 | n/a | n/a | -US$344m |
| Mar 31 2023 | n/a | n/a | -US$323m |
| Dec 31 2022 | US$8m | US$642k | -US$291m |
| Sep 30 2022 | n/a | n/a | -US$290m |
| Jun 30 2022 | n/a | n/a | -US$267m |
| Mar 31 2022 | n/a | n/a | -US$384m |
| Dec 31 2021 | US$9m | US$603k | -US$364m |
| Sep 30 2021 | n/a | n/a | -US$261m |
| Jun 30 2021 | n/a | n/a | -US$414m |
| Mar 31 2021 | n/a | n/a | -US$247m |
| Dec 31 2020 | US$4m | US$585k | -US$230m |
| Sep 30 2020 | n/a | n/a | -US$289m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$86m |
| Dec 31 2019 | US$4m | US$585k | -US$75m |
Compensatie versus markt: De totale vergoeding ($USD 19.77M ) Sanjiv } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.17M ).
Compensatie versus inkomsten: De vergoeding van Sanjiv is gestegen terwijl het bedrijf verliesgevend is.
CEO
Sanjiv Patel (50 yo)
7.7yrs
Tenure
US$19,770,838
Compensatie
Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.6yrs | US$581.14k | 0.14% $ 1.1m | |
| CEO, President & Director | 7.7yrs | US$19.77m | 0.82% $ 6.5m | |
| Co-Founder & Director | no data | US$548.64k | 0.60% $ 4.7m | |
| Chief Financial Officer | 6.6yrs | US$5.22m | 0.0069% $ 55.1k | |
| Chief Legal Officer & Secretary | 6.7yrs | US$4.51m | 0.026% $ 207.0k | |
| Chief Corporate Development Officer | no data | US$6.78m | 0.011% $ 88.5k | |
| President of Research & Development | 6.6yrs | US$8.57m | 0.042% $ 336.2k | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Founder | no data | geen gegevens | geen gegevens | |
| Chief Scientific Officer | less than a year | geen gegevens | geen gegevens | |
| Chief People Officer | no data | geen gegevens | geen gegevens |
6.6yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RLAY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.6yrs | US$581.14k | 0.14% $ 1.1m | |
| CEO, President & Director | 7.7yrs | US$19.77m | 0.82% $ 6.5m | |
| Co-Founder & Director | 8.3yrs | US$548.64k | 0.60% $ 4.7m | |
| Independent Director | 5.4yrs | US$548.64k | 0.015% $ 118.8k | |
| Independent Director | 6.1yrs | US$551.14k | 0% $ 0 | |
| Member of Oncology Advisory Board | 4.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 7.7yrs | US$551.14k | 0.024% $ 190.0k | |
| Member of Oncology Advisory Board | 4.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.1yrs | US$558.64k | 0.040% $ 319.4k | |
| Member of Oncology Advisory Board | 4.7yrs | geen gegevens | geen gegevens | |
| Member of Oncology Advisory Board | 4.7yrs | geen gegevens | geen gegevens | |
| Member of Oncology Advisory Board | 4.7yrs | geen gegevens | geen gegevens |
5.3yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RLAY wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).